protease inhibitors Indinavir: indinavir is also associated with indirect (unconjugated) hyperbilirubinemia due to inhibition of UGT.
Breastfeeding is an important risk factor for hyperbilirubinemia in healthy infants and is related to inadequate maternal milk supply in the first few days, decreased caloric intake and delayed passage of meconium.
Therefore, infants at risk for severe hyperbilirubinemia should be identified so they can be observed closely both while in the hospital and after discharge.
The mainstay in treatment of hyperbilirubinemia is phototherapy, which is safe and widely available.
Many infants who are readmitted to the hospital because of hyperbilirubinemia are mildly to moderately dehydrated.